PL.06 / ABOUT / EDITORIAL ENTITY
Who publishes this dossier
A standing report that reads the peer-reviewed research and regulatory filings on CJC-1295 in one place. Nothing is sold here. No clinicians are on staff. No medical advice is given.
What CJC-1295 Buy is
CJC-1295 Buy is a standing report on the public record for CJC-1295 — the peer-reviewed research, the FDA regulatory file, and the anti-doping standards, read together in one place. It runs no clinic, keeps no clinicians, and hands out no medical advice. It builds nothing, sells nothing, and distributes nothing. Its pages are a reading of published science, and every quantitative claim in them is sourced.
The word 'buy' in the domain marks a stance toward a high-volume search query about purchasing CJC-1295 — not a service this site offers. The report exists because the compound's regulatory, clinical, and analytical record is genuinely useful public-interest material, otherwise buried behind a wall of vendor product listings.
What this site is not
This site is not a pharmacy. It does not compound, dispense, ship, broker, or take payment for any peptide, drug, or chemical preparation.
This site is not a clinic, telehealth service, or medical practice. There are no physicians on staff. There are no pharmacists on staff. There are no nurses on staff. The site does not offer consultations, prescriptions, dosing recommendations, treatment protocols, or any other clinical service.
This site is not affiliated with any manufacturer, compounding pharmacy, research-chemical vendor, telehealth platform, or wellness clinic. We do not accept advertising. We do not run affiliate links. We do not direct readers to vendors.
This site does not, anywhere in its pages, recommend the use of CJC-1295 by any person for any purpose.
Editorial standards
Every quantitative claim on every page cites a primary source — a peer-reviewed paper, a ClinicalTrials.gov record, an FDA briefing document, or a published anti-doping standard. The full citation list appears at /references and is reproduced as a plain markdown file at /references.md for crawlers and reading clients.
Where the published record contradicts non-clinical or vendor-channel claims about CJC-1295, the dossier presents the published record. Where the published record is silent — for example, on long-term human safety and efficacy outcomes — the dossier says so explicitly rather than filling the gap with inference.
The dossier does not use brand names of FDA-approved drugs in other classes. Compounds are referred to by their international nonproprietary names or recognized chemical identifiers.
Sourcing methodology
The citation set assembled for this dossier covers the published peer-reviewed literature on CJC-1295 from the 2005 Jetté identification paper through the 2024 Thomas analytical methodology paper, the ClinicalTrials.gov record for NCT00267527, the October 2024 and December 2024 FDA Pharmacy Compounding Advisory Committee briefings, and the 2025 WADA Prohibited List. Adjacent comparator literature — the Stanley 2014 tesamorelin paper on visceral fat, the Bowers 1990 GHRH-plus-GHRP synergy paper, the Steiger 1992 GHRH-sleep paper — is included where it provides essential context for findings reported on CJC-1295 itself.
Where primary sources disagree, the dossier presents the disagreement explicitly rather than selecting a single interpretation.
Disclaimer
Everything published on this site is for research and informational purposes only and is not intended as medical advice. Nothing on this site is an offer to sell, an invitation to purchase, or a recommendation to use any compound, drug, or peptide preparation. CJC-1295 is not approved by the FDA or any other major regulator for human use. The site is not affiliated with any vendor, manufacturer, pharmacy, clinic, or telehealth service. Readers seeking medical guidance should consult a licensed healthcare professional.